Production & Manufacturing
BioPharma
Bora – Corealis Collaborate for Oral Solid Dose Development
Bora Pharmaceuticals Co. Ltd., which is a global leader when it comes to pharmaceutical manufacturing, along with a leading early-phase Contract Development Manufacturing Organization – CDMO, Corealis Pharma Inc., have gone on to enter into a strategic alliance so...
News
Iraq To Open Largest Cancer Drug Factory in The Region
Iraq looks forward to inaugurating the region’s largest cancer drug factory in Abu Ghraib, which is situated 32 kilometers – equivalent to 20 miles west of Baghdad, in December 2025 at a cost of around 50 million euros.
This step...
Business & Industry
400 Global Regulatory Manufacturing Approvals for Samsung Biologics
Samsung Biologics announced on November 26, 2025, that it has gone on to achieve a whopping 400 regulatory manufacturing approvals all over the world due to its quality competitiveness.
It is worth noting that as of November 2025, Samsung Biologics has secured...
BioPharma
Onshoring of Drug Product Manufacturing to Massachusetts
Moderna is set to expand its US manufacturing capabilities through the onshoring of drug product manufacturing to its present Moderna Technology Center - MTC located Norwood, Massachusetts, in a move that involves an investment of over $140m.
By way of this onshoring,...
BioPharma
The Rise of Pharma 4.0: Digital Twins, AI and Predictive Manufacturing
The pharmaceutical manufacturing industry stands at a transformative inflection point. For decades, manufacturing processes operated based on established protocols perfected through empirical experience and regulatory validation. While effective, these traditional approaches rely heavily on retrospective quality assurance, periodic environmental...
BioPharma
Advanced Sterile Manufacturing: Innovations Driving Aseptic Precision
Sterile pharmaceutical manufacturing represents one of the most technically demanding and highly regulated aspects of pharmaceutical production. The stakes are exceptionally high—any compromise in sterility assurance can render entire batches unusable or, worse, lead to contaminated products reaching patients...
BioPharma
Australian Biopharma to Expand US Plasma-Derived Therapies
The Australian-based biopharma company, CSL, plans to invest almost $1.5 billion in the next five years so as to expand its presence in the U.S. However, this is going to be subject to the approval from the board of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
















